Abstract: This invention relates to novel pyridine-based divalent metal ion chelating ligands of Formula I, wherein A or B are independently —R6R7, or —CH(R8)CH(R9). R1 to R9 are various substituents selected to optimize the physicochemical and biological properties such as enzyme binding, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics. The compounds of the present invention are useful for inhibiting the activity of viral enzymes responsible for the proliferation of human immunodeficiency virus (HIV).

Abstract: This invention relates to novel diaminopropane-based divalent metal ion chelating ligands of Formula I, wherein A is selected from the group consisting of —(CH2)a—, —(CH2)bO(CH2)c—, —(CH2O)d—, and —(CH2)eN(R4)(CH2)f—; a and c vary from 0 to 10; b, e, and f vary from 2 to 10, and d varies from 1 to 10. X and Y are independently —CR5R6, or —CH(R7)CH(R8). R1 to R8 are various substituents selected to optimize the physicochemical and biological properties such as enzyme binding, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 13. R1 to R8 may include, but are not limited to hydrogen, alkyl, acyl, hydroxyl, hydroxyalkyl, substituted or unsubstituted aryl, amino, aminoalkyl, alkoxyl, aryloxyl, carboxyl, halogen, alkoxycarbonyl, cyano, and other suitable electron donating or electron withdrawing groups. Ar may unsubstituted phenyl group or may be substituted with suitable electron donating or electron withdrawing groups.

Abstract: This invention relates to novel quinoline-based divalent metal ion chelating ligands of Formula I, wherein A or B are independently —CR7R8, or —CH(R9)CH(R10). X is hydrogen, C1-C10 alkyl; —OH, or —NR11R12. R1 to R12 are various substituents selected to optimize the physicochemical and biological properties such as enzyme binding, tissue penetration, lipophilicity, toxicity, bioavailability, and pharmacokinetics of compounds of Formula 13. R1 to R12 may include, but are not limited to hydrogen, alkyl, acyl, hydroxyl, hydroxyalkyl, substituted or unsubstituted aryl, amino, aminoalkyl, alkoxyl, aryloxyl, carboxyl, halogen, alkoxycarbonyl, cyano, and other suitable electron donating or electron withdrawing groups. The compounds of the present invention are useful for inhibiting the activity of viral enzymes responsible for the proliferation of human immunodeficiency virus (HIV).

Abstract: The present invention discloses novel steroid mimics wherein a tri- or tetravalent phosphorous atom is isosterically substituted at any one of the seventeen positions occupied by the carbon atom in the steroidal skeleton, and wherein each adjacent position to the phosphorous is either unsubstituted or optionally substituted by nitrogen or an oxygen atom to satisfy the valency of said phosphorous atom. The invention is illustrated schematically below using both aromatic and non-aromatic steroids. Although the isosteric substitution phosphorous atom in the above structures 3-7 is indicated at 13, 14, and 17 positions, it is to be noted that the phosphorous can be substituted at any one of the seventeen positions in non-aromatic or eleven positions in aromatic steroids. The phosphorous atom may be trivalent or tetravalent, and may be radioactive or non-radioactive. The adjacent atoms, X, Y, or Z may be carbon, oxygen, or nitrogen.